Initiate DAZALS Phase 2 trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2022
- Due
- 30 Sep 2022
- Delivered
- October 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“DAZALS, a 198-patient, randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in patients with ALS, planned to start this quarter”
What we found
Evidence strength A What the grades mean
The company announced a plan to initiate the DAZALS trial by September 30, 2022, but later filings confirm the trial was initiated in October 2022.
-
A Corcept Therapeutics Inc. 10-K filed 2023-02-28
“Following these compelling results, in October 2022 we initiated a Phase 2 trial of dazucorilant (the “DAZALS” trial) in patients with ALS.” ✓ confirmed on the page
Market reaction: the shares moved -6.6% against the S&P 500 over the three sessions around the disclosure (27 Feb 2023 to 2 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- DAZALS Phase 2 trial
- Target
- 198 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-CORT-002859 · Corrections policy